Questcor's shares were trading at $77 on the Nasdaq on Monday afternoon. Mallinckrodt was down 6 percent at $58.50 on the New York Stock Exchange. The deal - the latest in a series of acquisitions structured to take advantage of …
Questcor’s stock shot up 15 percent on Tuesday, the day its deal to acquire Synacthen was announced. “We believe the acquisition removes a key overhang as a potential competitor to Acthar is removed,” Biren Amin, an analyst at Jefferies …
Questcor and the charity have said they are victims of a campaign by short-sellers - investors who benefit from the decline of a stock’s price. Nonetheless, fearing defections from donors, the charity hired Venable, a law firm in Washington, to …
ANAHEIM — Mallinckrodt is buying Anaheim-based Questcor Pharmaceuticals Inc. for a combination of stock and cash valued at about $5.2 billion. Mallinckrodt makes a range of specialty pharmaceuticals. Questcor's primary product is …
Positive economic reports and strong earnings boosted markets to new highs Wednesday. Gross domestic product …
It's better news for Agios Pharmaceuticals (AGIO). The stock ended up over 25% after the company reported promising results in the first clinical trial of its leukemia drug. Questcor Pharmaceutical (QCOR)was one of the top trending …
Most analysts tracking Questcor Pharmaceuticals are still rating it a buy, despite the stock diving nearly 50% on Wednesday over concerns that insurance companies were moving to limit coverage of the company’s primary revenue …
These companies are selected based on a number of requirements, including having an annual revenue between $5 million and $1 billion, they need to have traded for more than a year, and boast a stock price ... on their way up. Questcor